Eton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from Analysts at B. Riley

Analysts at B. Riley initiated coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a note issued to investors on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $21.00 price target on the stock. B. Riley’s price objective would suggest a potential upside of 74.85% from the company’s current price.

ETON has been the topic of a number of other reports. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright boosted their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday.

Eton Pharmaceuticals Trading Up 0.2 %

Shares of ETON opened at $12.01 on Friday. The company’s 50-day moving average price is $11.64 and its 200 day moving average price is $7.35. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00. The firm has a market cap of $312.87 million, a P/E ratio of -54.59 and a beta of 1.38.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $54,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals in the third quarter valued at $90,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares during the period. Renaissance Technologies LLC grew its stake in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in Eton Pharmaceuticals during the 2nd quarter worth about $362,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.